Chapter 23. Bleeding disorders associated with coagulopathy

Slides:



Advertisements
Similar presentations
Coagulopathies Hayley Morse May 29, 2008.
Advertisements

Hemostasis Shaina Eckhouse 10/12/2010.
Basic coagulation techniques and Quality control issues
Hemorrhagic diseases. Lesions of the blood vessels Lesions of the blood vessels Abnormal platelets Abnormal platelets Abnormalities in the coagulation.
Pre-analytical factors that can affect coag test results
Initiation substances activate s by proteolysis a cascade of circulating precursor proteins which leads to the generation of thrombin which in turn converts.
HEMOSTASIS/THROMBOSIS II Congenital/Acquired Hemorrhagic Disorders & Their Treatment.
Bachelor of Chinese Medicine, The University of Hong Kong Bleeding disorders Dr. Edmond S. K. Ma Division of Haematology Department of Pathology The University.
Basic Principles of Hemostasis
Hemostasis: Hemostasis: Hemo/Stasis Hemo=خونStasis=سکون.
HEMOSTAZ Yard. Doç. Dr. Murat ÖRMEN. Vessels Platelets Fibrinolysis/Inhibitors Coagulation Proteins BleedingClotting Hemostaz.
Bleeding and coagulation disorders
Gatmaitan, Raymond Vincent Golpeo, Kirsten C.
Bleeding disorders. By Dr Abiodun Mark .A.
MLAB 1227: Coagulation Keri Brophy-Martinez
Bleeding time,clotting time, PT, and PTT
Approach to the Bleeding Patient
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Inherited Coagulation Disorders Dr Galila Zaher Consultant Hematologist KAUH.
Blood coagulation involves a biological amplification system in which relatively few initiation substances sequentially activate by proteolysis a cascade.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
Lecture NO- 12- Dr: Dalia Kamal Eldien.  Coagulation: Is the process by which blood changes from a liquid to a clot. Coagulation begins after an injury.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Hemostasis and Blood Coagulation
FUNCTIONS OF THE COAGULATION SYSTEM ACTIONDESIRED RESULT Rapid formation of mechanically sound clot Stop bleeding quickly Prevent clot formation at non-injured.
Secondary Hemostasis Part One MLAB Coagulation Keri Brophy-Martinez.
Bleeding Disorders Dr. Farjah H.AlGahtani
Approach to Bleeding Disorders
HAEMOSTASIS AND THROMBOSIS. The integrity of the circulation is maintained by blood flowing through intact vessels lined by endothelial cells. Injury.
1 HAEMOSTASIS. 2 Definition Haemostasis is a complex sequence of physical and biochemical changes induced by damage to tissues and blood vessels, which.
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
MLAB 1227: Coagulation Keri Brophy-Martinez Coagulation Disorders: Secondary Hemostasis Part Two.
Disseminated Intravascular Coagulation. XIIa Coagulation cascade IIa Intrinsic system (surface contact ) XII XI XIa Tissue factor IX IXa VIIa VII VIIIVIIIa.
The hemophilias A and B X-linked hereditary blood clotting disorders due to deficiency of factor VIII (hemophilia A) or factor IX (hemophilia B) Identical.
February 4 th, The Child With Pain Single Joint Involvement Multiple Joint Involvement With Fever Septic arthritis/Osteomyelitis Sympathetic arthritis.
APTT. Causes of prolonged aPTTs: 1.Spurious (common to many Coag tests): – dilution (saline, Tx), underfilled specimen, clotted, prolonged tourniquet.
Investigation of Haemostasis MS. c. program Lab-9.
Inherited bleeding disorder of primary hemostasis.
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
HEMOSTASIS When blood vessels are cut or damaged, the loss of blood from the system must be stopped before shock and possible death occur. This is accomplished.
Physiology of Blood. Platelets Small granulated non-nucleated bodies 2-4 micron in diameter Life span….. 8 days Count…300,000/mm 3.
Von Willebrand’s Disease. vWD Family of bleeding disorders Family of bleeding disorders Caused by a deficiency or an abnormality of von Willebrand Factor.
INHERITED DISORDERS OF COAGULATION von Willebrand Disease 1.
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 26 Disorders of Hemostasis.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
Approach to the Bleeding Child. Evaluation  History Current Bleeding Medical Family  Physical exam  Selected laboratory investigations.
거핵구 (Megakaryocytic). Thrombocyte(Platelets ) Platelet Satelitism ( 혈소판 위성현상 ) EDTA Pseudothrombocytopenia.
Coagulation tests CBC- complete blood count
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
Obada Al-Eisa Saud Bashtawy Emad Mansour.  It is an acquired condition characterized by massive activation of the coagulation system.  It is always.
Rafi Ahmed, MD Hematology Oncology Fellow
Congenital bleeding disorders
Approach To Bleeding Disorders In Neonates
Secondary Haemostasis
Pre-analytical factors that can affect coag test results
Chapter 18 Disorders of Hemostasis
These factors prevent blood clotting - in normal state.
Biochemistry of Coagulation
General Principles of Hemostasis Kristine Krafts, M.D.
Diagnosis Approach of Bleeding in Children ________________________________ Ketut Ariawati Hematologi Onkologi RSUP Sanglah Denpasar.
Constituents of the blood: Platelets and plasma
Hemodynamic disorders (1 of 3)
Intrinsic pathway Formation of prothombin activator is the central event in the clotting pathway For its formation the pathway that is initiated by.
General Principles of Hemostasis Kristine Krafts, M.D.
Principles of Coagulation Screening II
Dr. Ahmed Hassaneen Coagulation disorders.
Presentation transcript:

Chapter 23. Bleeding disorders associated with coagulopathy O bleeding platelet count, bleeding time, capillary fragility test: normal PT, aPTT: prolonged -> coagulation factor, fibrinogen deficiency O hereditary (hemophilia A, B, C, von Willebrand disease) vs acquired 01. Bleeding disorders associated with congenital coagulopathy 1. Hemophilia A O factor VIII deficiency (reduced amount or activity) O sex-linked recessive O the most common coagulopathy O severe hemophilia A: inversion mild-moderate hemophilia A: missense mutation

release of blood protease into the synovial space O clinical presentation: delayed and spontaneous nature of the bleeding - acute hemarthrosis release of blood protease into the synovial space -> cartilage destruction -> joint destruction - intramuscular hemorrhage - central nervous system bleeding: the most common cause of death O aPTT: prolonged O PT, bleeding time, thrombin clotting time (TCT): normal O specific coagulation factor assay for factor VIII (40%)

O von Willebrand disease: factor VIII activity (VIII:C) -> reduced 2. Hemophilia B O factor IX deficiency O sex-linked recessive O clinical presentation: identical to those of hemophilia A O aPTT: prolonged PT, thrombin clotting time, Bleeding time: normal specific factor assay for factor IX 3. Hemophilia C O factor XI deficiency (activated by thrombin) O autosomal recessive specific factor assay for factor XI

4. Von Willebrand disease O defect in vWF O heterogenous disorder O vWF: participates in primary hemostasis carrier protein for factor VIII (stability) exists as a series of oligomer (from dimer to oligomer) synthesized in endothelial cell (Weibel-Palade body), megakaryocyte N: VIII binding site M: collagen, GPIb-IX-V binding site (A domain) C: GPIIb-IIIa binding site (C1 domain) O clinical presentation: platelet-type bleeding O lab evaluation -bleeding time: prolonged (cf. platelet disorder, connective disorder) -Ristocetin cofactor activity (Ristocetin-induced platelet agglutination): 감소 restocetin -> structural change of vWF -> exposing A domain -> induce agglutination of platelet -plasma vWF antigen -Factor VIII activity (using aPTT) -Multimer analysis type I vWD: overall decreased but normal array of vWF multimers type II vWD: abnormal multimer pattern type III vWD: absence of all vWF multimers

5. 기타 유사혈우병 질환 (1) Factor XII, prekalikrein, HMWK O not associated with bleeding O aPTT: prolonged O because in vivo they do not participate in hemostasis (2) Factor II, X, V (in common pathway) O rare disorders O PT, aPTT: prolonged bleeding time, thrombin clotting time: normal O V deficiency: parahemophilia (3) Factor VII (in extrinsic pathway) O isolated prolonged PT aPTT, bleeding time, thrombin clotting time: normal (4) Disorders of fibrinogen O hereditary afibrinogenemia O hereditary hypofibrinogenemia O dysfibrinogenemia O PT, aPTT, thrombin clotting time: prolonged (5) Factor XIII deficiency O PT, aPTT, thrombin clotting time, platelet count, bleeding time: normal O Urea clot solubility test: shortened

02. Acquired coagulopathy and Bleeding disorders O cause: medication, underlying disease 1. Anticoagulant agents O Heparin: antithrombin III -> thrombin O warfarin (Coumadin): vitamin K antagonist -> II, X, IX, VII, protein C,S O Low-molecular weight heparin: Xa 2. DIC O cause bleeding (consumptional coagulopathy) or thrombosis (혈액순환장애) -> shock, acidosis O simultaneous presence of thrombin and plasmin O acute DIC: hemorrhagic condition chronic DIC: prothrombic condition O antithrombin III, alpha2-antiplasmin: decrease 3. Liver disease O liver: synthesize all coagulation proteins clears plasmin

4. Vitamin K deficiency O water insoluble O nutritionally depleted/ malabsorption (bile juice deficiency) O warfarin O antibiotics 5. Massive transfusion O dilution of plasma and platelet O increased concentrations of the anticoagulant sodium citrate 6. Uncommon acquired coagulation protein defects O dysfibrinogenemia O inhibitors (antibody) to coagulation factors O hypergammaglobulinemic states (coagulation inhibition) O malignancy: produce heparinoids 7. Uremia (요독증) O blood vessel damage O coagulation deficiency O platelet defects 8. Hyperfibrinolysis